Advances and challenges in nintedanib drug delivery

Velagacherla, Varalakshmi and Suresh, Akhil and Mehta, Chetan H and Nayak, Usha Y (2021) Advances and challenges in nintedanib drug delivery. Expert Opinion on Drug Delivery, 18 (11). pp. 1687-1706. ISSN 1742-5247

[img] PDF
14198.pdf - Published Version
Restricted to Registered users only

Download (6MB) | Request a copy


Introduction: Nintedanib (N.T.B) is an orally administered tyrosine kinase inhibitor that has been approved recently by U.S.F.D.A for idiopathic pulmonary fibrosis (I.P.F) and systemic sclerosisassociated interstitial lung disease (S.Sc-I.L.D). N.T.B is also prescribed in COVID-19 patients associated with I.P.F. However, it has an extremely low bioavailability of around 4.7%, and hence, researchers are attempting to address this drawback by different approaches.Areas covered: This review article focuses on enlisting all the formulation attempts explored by researchers to increase the bioavailability of N.T.B while also providing meaningful insight into the unexplored areas in formulation development, such as targeting of the lymphatic system and transdermal delivery. All the patents on the formulation development of N.T.B have also been summarized.Expert opinion: N.T.B has the potential to act on multiple diseases that are still being discovered, but its extremely low bioavailability is a challenge that is to be dealt with for obtaining the full benefit. Few studies have been performed aiming at improving the bioavailability, but there are unexplored areas that can be used, a few of which are explained in this article. However, the ability to reproduce laboratory results when scaling up to the industry level is the only factor to be taken into consideration

Item Type: Article
Uncontrolled Keywords: Bioavailability; COVID-19; Idiopathic pulmonary; Fibrosis; Nintedanib; Systemic sclerosis-associated interstitial lung disease
Subjects: Pharmacy > MCOPS Manipal > Pharmaceutics
Depositing User: KMC Library
Date Deposited: 28 Jan 2022 03:50
Last Modified: 28 Jan 2022 03:50

Actions (login required)

View Item View Item